Loading...
•
Sep 30, 2022
Merck Q3 2022 Earnings Report
Merck's Q3 2022 financial results demonstrated exceptional revenue and underlying earnings growth, driven by oncology, vaccines, and hospital acute care products.
Key Takeaways
Merck reported strong Q3 2022 results, with revenue increasing by 13% to $13.0 billion in Pharmaceutical sales and Non-GAAP EPS of $1.85. The growth was primarily driven by Keytruda and Gardasil sales.
Third-quarter pharmaceutical sales increased 13% to $13.0 billion.
Growth in oncology was largely driven by higher sales of KEYTRUDA, which rose 20% to $5.4 billion in the quarter.
Third-quarter GARDASIL/GARDASIL 9 sales grew 15% to $2.3 billion, primarily driven by strong demand outside of the U.S., particularly in China.
Non-GAAP EPS was $1.85 for the third quarter of 2022 compared to $1.78 for the third quarter of 2021.
Merck
Merck
Merck Revenue by Segment
Revenue by Segment
Pharmaceutical Revenue
CapyFin.comAnimal Health Revenue
CapyFin.com Forward Guidance
Merck is raising and narrowing its full-year outlook for sales and non-GAAP EPS, despite a negative impact from foreign exchange.
Positive Outlook
- Merck expects sales growth of 20% to 21% in 2022, with full-year sales estimated to be between $58.5 billion and $59.0 billion.
- Excluding LAGEVRIO, Merck expects sales growth of approximately 12% for full-year 2022.
- Merck expects its full-year non-GAAP effective income tax rate to be approximately 14%.
- Merck is raising and narrowing its expected full-year 2022 non-GAAP EPS to be between $7.32 and $7.37.
- The company is narrowing its expected full year sales range of LAGEVRIO to be between $5.2 billion and $5.4 billion.
Challenges Ahead
- Merck continues to experience strong global momentum across its key pillars of growth, particularly in oncology and vaccines. As a result, Merck is raising and narrowing its full-year outlook for sales and non-GAAP EPS, despite a negative impact from foreign exchange.
- At mid-October 2022 exchange rates, Merck expects sales growth of 20% to 21% in 2022, with full-year sales estimated to be between $58.5 billion and $59.0 billion, including a negative impact from foreign exchange of approximately 4%, including a less than 1% incremental negative impact from prior sales outlook.
- Merck is lowering its expected full-year 2022 GAAP EPS to be between $5.68 and $5.73.
- Merck is raising and narrowing its expected full-year 2022 non-GAAP EPS to be between $7.32 and $7.37, including a negative impact from foreign exchange of approximately 4% at mid-October exchange rates.
- Operational strength of approximately $0.20 is partially offset by the following negative impacts, which were not reflected previously in the outlook: The non-GAAP range excludes acquisition- and divestiture-related costs and costs related to restructuring programs as well as income and losses from investments in equity securities.